PDF herunterladen
Semin intervent Radiol 2015; 32(02): 231-236
DOI: 10.1055/s-0035-1549846
Clinical Corner
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

A Focused Review of the Pathogenesis, Diagnosis, and Management of Tumor Lysis Syndrome for the Interventional Radiologist

Marcia Friedman
1   Division of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, Illinois
,
Pritesh R. Patel
1   Division of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, Illinois
2   University of Illinois Cancer Center, Chicago, Illinois
,
Damiano Rondelli
1   Division of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, Illinois
2   University of Illinois Cancer Center, Chicago, Illinois
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
28. Mai 2015 (online)

Auch verfügbar auf
    Lizenzen und Reprints

The tumor lysis syndrome (TLS) is one of the most frequently encountered and dangerous oncologic emergencies.[1] TLS describes a constellation of laboratory and clinical findings resulting from the rapid breakdown of tumor cells releasing their intracellular contents into the systemic circulation. It occurs most commonly in hematologic malignancies at the start of antineoplastic therapy, but has also been reported in a broad variety of solid organ malignancies, as well as occurring spontaneously without chemotherapy.[2] [3] [4] [5] As a potentially fatal oncologic emergency, it is imperative to identify patients at risk for early preventative therapy, understand the pathophysiology and consequences of this syndrome, and recognize the clinical and laboratory manifestations of TLS to ensure timely and appropriate treatment.

 

  • References

  • 1 Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011; 364 (19) 1844-1854
    CrossrefPubMedGoogle Scholar
  • 2 Mirrakhimov AE, Ali AM, Khan M, Barbaryan A. Tumor lysis syndrome in solid tumors: an up to date review of the literature. Rare Tumors 2014; 6 (2) 5389
    PubMedGoogle Scholar
  • 3 Vaisban E, Braester A, Mosenzon O, Kolin M, Horn Y. Spontaneous tumor lysis syndrome in solid tumors: really a rare condition?. Am J Med Sci 2003; 325 (1) 38-40
    CrossrefPubMedGoogle Scholar
  • 4 Baeksgaard L, Sørensen JB. Acute tumor lysis syndrome in solid tumors—a case report and review of the literature. Cancer Chemother Pharmacol 2003; 51 (3) 187-192
    PubMedGoogle Scholar
  • 5 Jasek AM, Day HJ. Acute spontaneous tumor lysis syndrome. Am J Hematol 1994; 47 (2) 129-131
    CrossrefPubMedGoogle Scholar
  • 6 Cairo MS, Coiffier B, Reiter A, Younes A ; TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149 (4) 578-586
    CrossrefPubMedGoogle Scholar
  • 7 Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26 (16) 2767-2778
    CrossrefPubMedGoogle Scholar
  • 8 Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127 (1) 3-11
    CrossrefPubMedGoogle Scholar
  • 9 Montesinos P, Lorenzo I, Martín G , et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 2008; 93 (1) 67-74
    CrossrefPubMedGoogle Scholar
  • 10 Mato AR, Riccio BE, Qin L , et al. A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma 2006; 47 (5) 877-883
    CrossrefPubMedGoogle Scholar
  • 11 Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993; 94 (2) 133-139
    CrossrefPubMedGoogle Scholar
  • 12 Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004; 116 (8) 546-554
    CrossrefPubMedGoogle Scholar
  • 13 Sklarin NT, Markham M. Spontaneous recurrent tumor lysis syndrome in breast cancer. Am J Clin Oncol 1995; 18 (1) 71-73
    CrossrefPubMedGoogle Scholar
  • 14 Hsieh PM, Hung KC, Chen YS. Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review. World J Gastroenterol 2009; 15 (37) 4726-4728
    CrossrefPubMedGoogle Scholar
  • 15 Tsai WL, Liang PC, Chen CH. Tumor lysis syndrome after transarterial chemoembolization plus portal venous embolization for hepatocellular carcinoma. J Formos Med Assoc 2012; 111 (12) 724-725
    CrossrefPubMedGoogle Scholar
  • 16 Wössmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003; 82 (3) 160-165
    PubMedGoogle Scholar
  • 17 Annemans L, Moeremans K, Lamotte M , et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 2003; 44 (1) 77-83
    CrossrefPubMedGoogle Scholar
  • 18 Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol 2000; 27 (3) 322-334
    PubMedGoogle Scholar
  • 19 Boles JM, Dutel JL, Briere J , et al. Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer 1984; 53 (11) 2425-2429
    CrossrefPubMedGoogle Scholar
  • 20 Kanfer A, Richet G, Roland J, Chatelet F. Extreme hyperphosphataemia causing acute anuric nephrocalcinosis in lymphosarcoma. BMJ 1979; 1 (6174) 1320-1321
    PubMedGoogle Scholar
  • 21 Shimada M, Johnson RJ, May Jr WS , et al. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transplant 2009; 24 (10) 2960-2964
    CrossrefPubMedGoogle Scholar
  • 22 Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones—a rare complications of allopurinol therapy. N Engl J Med 1969; 280 (8) 426-427
    CrossrefPubMedGoogle Scholar
  • 23 LaRosa C, McMullen L, Bakdash S , et al. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol 2007; 22 (1) 132-135
    CrossrefPubMedGoogle Scholar
  • 24 Pais Jr VM, Lowe G, Lallas CD, Preminger GM, Assimos DG. Xanthine urolithiasis. Urology 2006; 67 (5) 1084.e9-1084.11
    PubMedGoogle Scholar
  • 25 Conger JD, Falk SA. Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 1977; 59 (5) 786-793
    CrossrefPubMedGoogle Scholar
  • 26 DeConti RC, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 1966; 274 (9) 481-486
    CrossrefPubMedGoogle Scholar
  • 27 Goldman SC, Holcenberg JS, Finklestein JZ , et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97 (10) 2998-3003
    CrossrefPubMedGoogle Scholar
  • 28 Pui CH, Mahmoud HH, Wiley JM , et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol 2001; 19 (3) 697-704
    PubMedGoogle Scholar
  • 29 Coiffier B, Mounier N, Bologna S , et al; Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21 (23) 4402-4406
    CrossrefPubMedGoogle Scholar
  • 30 Jeha S, Kantarjian H, Irwin D , et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005; 19 (1) 34-38
    PubMedGoogle Scholar
  • 31 Bosly A, Sonet A, Pinkerton CR , et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003; 98 (5) 1048-1054
    CrossrefPubMedGoogle Scholar
  • 32 Galardy PJ, Hochberg J, Perkins SL, Harrison L, Goldman S, Cairo MS. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report. Br J Haematol 2013; 163 (3) 365-372
    CrossrefPubMedGoogle Scholar
  • 33 Cortes J, Moore JO, Maziarz RT , et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol 2010; 28 (27) 4207-4213
    CrossrefPubMedGoogle Scholar
  • 34 Lopez-Olivo MA, Pratt G, Palla SL, Salahudeen A. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. Am J Kidney Dis 2013; 62 (3) 481-492
    CrossrefPubMedGoogle Scholar
  • 35 Cheuk DK, Chiang AK, Chan GC, Ha SY. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database Syst Rev 2014; 8: CD006945
    PubMedGoogle Scholar
  • 36 Saylor PJ, Reid TR. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol 2007; 25 (23) 3544-3546
    CrossrefPubMedGoogle Scholar
  • 37 Lee MH, Cheng KI, Jang RC, Hsu JH, Dai ZK, Wu JR. Tumour lysis syndrome developing during an operation. Anaesthesia 2007; 62 (1) 85-87
    CrossrefPubMedGoogle Scholar
  • 38 Stein JE, Schwenn MR, Jacir NN, Harris BH. Surgical restraint in Burkitt's lymphoma in children. J Pediatr Surg 1991; 26 (11) 1273-1275
    CrossrefPubMedGoogle Scholar
  • 39 Stovroff MC, Coran AG, Hutchinson RJ. The role of surgery in American Burkitt's lymphoma in children. J Pediatr Surg 1991; 26 (10) 1235-1238
    CrossrefPubMedGoogle Scholar